I. Vázquez

发表

Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism.

A. Sablina, J. Swinnen, Yanyan Cai, 2016, Cancer cell.

ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia

J. Minna, F. Prósper, M. Calasanz, 2006, Oncogene.

Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia

J. Minna, F. Prósper, M. Calasanz, 2006, International journal of cancer.

The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.

M. Odero, I. Vázquez, I. Cristóbal, 2017, Biochimica et biophysica acta. Gene regulatory mechanisms.

Biological and clinical significance of dysplastic hematopoiesis in patients with newly-diagnosed multiple myeloma.

F. Prósper, R. Valdés-Mas, Marcos González, 2020, Blood.

Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data.

F. Prósper, M. Calasanz, I. Vázquez, 2020, Leukemia research.

NUP 98 Is Fused to Adducin 3 in a Patient with T-Cell Acute Lymphoblastic Leukemia and Myeloid Markers , with a New Translocation t ( 10 ; 11 ) ( q 25 ; p 15 ) 1

J. Cigudosa, X. Agirre, J. Vizmanos, 2003 .

NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15).

J. Cigudosa, M. Odero, M. Calasanz, 2003, Cancer research.

Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements

M. Odero, M. Calasanz, X. Agirre, 2004, Genes, chromosomes & cancer.

The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival

F. Prósper, Marcos González, J. Miguel, 2016 .

Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription

M. Odero, M. Calasanz, C. Vicente, 2013, Oncogene.

Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.

E. Andreu, F. Prósper, M. Odero, 2005, Cancer genetics and cytogenetics.

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

M. Calasanz, X. Agirre, A. Oriol, 2022, Cancers.

Cryptic ins(2;11) with clonal evolution showing amplification of 11q23–q25 either on hsr(11) or on dmin, in a patient with AML-M2

N. Zeleznik-Le, M. Ardanaz, M. Odero, 2004, Leukemia.

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

F. Prósper, M. Calasanz, M. Sanz, 2022, Blood advances.

Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms

F. Prósper, M. Calasanz, E. Bandrés, 2020, Journal of clinical medicine.

Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

F. Prósper, J. Hernández-Rivas, J. Sierra, 2011, Haematologica.

Downregulation of EVI 1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

F. Prósper, J. Hernández-Rivas, J. Sierra, 2011 .

FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome

P. Pelicci, M. Odero, M. Calasanz, 2005, Human Genetics.

Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia

F. Prósper, X. Agirre, M. Barrios, 2005, Leukemia.

Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells

P. Pelicci, M. Odero, M. Calasanz, 2004, Oncogene.

JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers

M. Odero, M. Calasanz, E. Bandrés, 2007, Leukemia.

JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers

M. Odero, M. Calasanz, E. Bandrés, 2007, Leukemia.

Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia

F. Prósper, M. Odero, M. Calasanz, 2010, Proceedings of the National Academy of Sciences.

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

M. Tormo, M. González-Díaz, M. Calasanz, 2020, Haematologica.

p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors.

A. Sablina, E. V. Van Limbergen, I. Vázquez, 2014, Cancer research.

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling

S. Tejpar, A. Sablina, E. Budinská, 2014, Oncotarget.

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia

J. Cigudosa, F. Solé, J. Hernández-Rivas, 2019, British journal of haematology.

Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design

F. Prósper, M. Calasanz, I. Vázquez, 2020, PloS one.

Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.

Sebastian Munck, Wen Chen, S. Munck, 2012, Cancer research.

Predicts Tumor Sensitivity to PARP Inhibition Loss of PPP 2 R 2 A Inhibits Homologous Recombination DNA Repair

S. Munck, A. Sablina, I. Vázquez, 2012 .

Molecular and Cellular Pathobiology Loss of PPP 2 R 2 A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition

Sebastian Munck, Wen Chen, S. Munck, 2012 .

Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

M. Tormo, M. Calasanz, E. Barragán, 2022, Cancers.

Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter

F. Prósper, M. Calasanz, X. Agirre, 2006, British journal of haematology.

ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia

J. Minna, F. Prósper, M. Calasanz, 2013, Oncogene.

NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2.

M. Odero, M. Calasanz, X. Agirre, 2005, Cancer genetics and cytogenetics.

Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities

M. Odero, M. Calasanz, I. Lahortiga, 2012, Leukemia.

EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2

M. Odero, M. Calasanz, E. Bandrés, 2010, British Journal of Cancer.

Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription

M. Odero, M. Calasanz, I. Vázquez, 2013, Oncogene.

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling

S. Tejpar, A. Sablina, E. Budinská, 2014, Oncotarget.

Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.

S. Munck, A. Sablina, I. Vázquez, 2012, Cancer research.